De la metadona al LAAM: Nuevos perfiles terapéuticos. Utilidad de la monitorización terapéutica (MT)

Mª Dolores Baño, Mª L. López, M. Agujetas, V. Muñoz, J.L. Guillén

Resumen


La introducción del LAAM en el tratamiento farmacológico de la dependencia a opiáceos, supone un avance importante, al poder diversificar el uso de opioides que hasta el momento, en nuestro país, se había reducido a la metadona. El objetivo de este trabajo ha sido la identificación de nuevos perfiles de uso del LAAM , teniendo en cuenta aspectos farmacocinéticos y posibles interacciones con otros fármacos y apoyado por los resultados obtenidos sobre niveles plasmáticos de metadona y su posible aplicación al LAAM. En el momento actual, su perfil de uso sólo ha sido para pacientes en metadona estabilizados, con buena respuesta al tratamiento, y a los que se deseaba flexibilizar y espaciar la administración diaria . En este artículo se proponen otros perfiles de uso, tales como programas de alto umbral orientados al cambio con desintoxicación y posterior paso a programa libre de drogas y sobre todo pacientes en metadona que pierden estabilidad y presentan síndrome de abstinencia a opiáceos, con disminución de los niveles plasmáticos de metadona, debido a interacciones medicamentosas o a otros motivos. Será necesario realizar estudios con los perfiles propuestos, que amplíen el uso del LAAM para pacientes que tienen problemas con la metadona, como una alternativa terapeútica, complementada con la monitorización en plasma como un instrumento de ayuda y evaluación que mejore la eficacia de los mismos.


Palabras clave


metadona; LAAM; niveles plasmáticos de metadona; farmacocinética; nuevos perfiles

Texto completo:

PDF

Referencias


• Altice F.I., Friedland G.H., Cooncy E.L.(1999) Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS Vol. 13:957-962.

• Ball J.C, Lange R.W, MyersC.P.(1988)Reducing the risk of AIDS through methadone maintenance treatment. Journal Of Health and social behavior. 29:214-226.

• Baño M.D.,Agujetas M., López M.L., Millán I., Lora Tamayo C., Guillén J.L.(1998). Resultados del estudio piloto realizado en el Programa Municipal de Drogas de Majadahonda sobre niveles plasmáticos de metadona. En: Cabrera J.,Guillén J.L.eds. La huella de la metadona:

Niveles plasmáticos. Un instrumento clínico para mejorar tratamientos. Madrid Delos S.L.123-146.

• Baño M.D., Agujetas M., López M.L., Guillén J.L.(2000) La nevirapina induce síntomas de abstinencia en pacientes en programa de mantenimiento con metadona con infección VIH. Revista Clinica Española. 200 (1):18-20.

• Baño M.D., López M.L, Agujetas M., Millán I., Guillén J.L.(2000).Niveles plasmáticos de metadona. Resultados después de 15 meses de seguimiento en el Programa Municipal de Drogas de Majadahonda. Adicciones."en prensa".

• Bammer G. (1997) Practical issues of pharmacotherapy availability and trialing Chapter III. In: Ritter A., Kutin J., Lintzeris N., Bammer G.(eds). Expanding treatment options for heroin dependence in Victoria:

buprenorphine, LAAM, naltrexone and slow release oral morphine. New Pharmacotherapies Project-Feasibility Phase. Fitzroy, Victoria: Turning point alcohol and drug centre Inc.

• Billings RE.(1973). Metabolism of acetlymethadol. A sensitive assay for nor-acetylmethadol and the identification of a new active metabolite. J.Med Chem . 16:305-306.

• Brugal MT,Puigdollers E (1999).Evluación de la efectividad de diferentes subprogramas de metadona. Adicciones. 11(1):6-7.

• Finkle, B.S., Jennison, T.A., Chinn, D.M., Ling, W., Holmes, E.D. (1982).Plasma and urine disposition of 1-alphaacetylmethadol and its principal metabolites in man. Journal of Analytical Toxicology. 6: 100-105.

• De Castro J. (1996). The effects of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of metadone.Biopharm-Drug-Dispos.17(7): 551-63

• Dole V.P. Foreword (1991). In The efectiveness of methadonemaintenance treatment. Ball J.C and Ross A. Eds. Springer, New york. VII-VIII.

• Fraser H.F, Isbell H.F. (1952) Actions and addiction liabilities of alpha-acetylmethadol in man. J. Pharmacol Exp ther. 105: 458-465.

• Fraser, H.F., Nash,T.L., Vanhorn, G.D., Isbell,H.(1954) Use of miotic effect in evaluating analgesic drugs in man. Archives Internationales des Pharmacodynamie et de Therapie. 98:443-451

• Freedman R.R, & Czertko, G.(1981).A comparison of thwice weekly LAAM and daily methadone in employed heroin addicts. Drug and Alcohol Dependence.8(3):215-222.

• Gamaleya N, Tronnikov S, Ulyanova L, Klimova S; Dmitrieva I.(1996) Antibodies to morphine and impaired immune reactivity. Addict Biol. 1: 437-445

• Gamaleya N, Dmitrieva I, Borg S, Ericson N.(1999) Induction of antibodies to methadone during methadone maintenance treatment of heroin addicts and its possible clinical implications. Eur. J. Pharmacol. 26:369 (3):357-64.

• Garrido MJ, Valle M, Calvo R, Troconiz IF.(1999).Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther. Jan. 288 (1):179-87.n

• Glass R.M(1993): Methadone maintenance: New research on a controversial treatment(editorial). JAMA. 269:1995-1996.

• Goode PG (1971).And implanted reservoir of morphine solution for rapid induction of physical dependence in rats. Br J Pharmacol. 41:558-566.

• Guillén JL., López ML(1998)Técnica analítica para la determinación de niveles plasmáticos de metadona. En: CabreraJ.Guillén JL.eds. La Huella de la Metadona. Niveles plasmáticos. Un instrumento clínico para

mejorar tratamientos. Delos. S.L. Madrid .457-472.

• Hall W, Bell J, Carless J.(1993) Crime and drug use among applicants for methadone maintenance. Drug Alcohol Dependence.31:123-129.

• Heelon M.W., Meade LB.(1999)Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy. 19(4).471-2.

• Henderson GL, Wilson BK, Derick HM. (1976). Plasma lalpha-acetylmethadol after acute and chronic administration. Clin.Pharmacol.Ther. 21: 16-25.

• Hiltunen AJ.,Lafolie P, Martel J, Ottosson F-C Boreus L.O, Beck O, Borg S, Hjemdahl P. (1995) Subjetive and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychopharmacology. 118: 122-126.

• Hubbard RL, Marsden ME., Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM.(1989) Drug Abuse Treatment: A National Study of Effectiveness. Chapell Hill, Universty of North Carolina Press.

• Inturrisi CE , Verebely K.(1972). The levels of methadone in the plasma in methadone maintenance. Clin. Pharmacol Ther. 13: 633-637.

• Inturrisi C.E. (1987).Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol.Ther. 41: 392-401.

• Jaffe, J.H., Senay, E.C. Schuster, C.R.(1972) .Methadyl acetate vs. methadone: a double-blind study in heroin users. Journal of the American Medical Association. 3: 21-26.

• Jaffe JH, Schuster CR, Smith BB, Blachyl PH.(1976). Comparison of acetyl methadol and methadone in the treatment of long term heroin users: A pilot study National Institute on Drug Abuse Research Monograph. Nº 8, Washington, DC, Government Printing Office, 72-73.

• Jaffe JH, y Martin W.(1985) Opioid analgesics and antagonists. In A.G.Gilman L.S.Goodman,T.W. Rall y F.Murad (Eds). Goodman and Gilman´s .The pharmacological basis of therapeutics 7Th.ed. N.Y:Macmillan. 491-531.

• Jaffe J.H.(1990) Drogadicción y abuso de drogas En : Bases farmacológicas de la terapeútica. Goodman y Gilman eds. Madrid Ed. Panamericana. 513-560.

• Johnson R, Chutuape MA, Strain E, Walsh S, Stitzer M, Bigelow E. (2000) A comparison of levomethadyl acetate, buprnorphine, adn methadone for opioid dependence. The New England Jorunal of Medicine. 343(18) : 1290-1297

• Kaiko RF, Inturrisi CE. (1975) Disposition of acetylmethadol in relation to pharmacologic action. Clin. Pharmacol Ther. 18: 96-103.

• Kang SY, De Leon G. (1993) Correlates of drug injection behaviours among methadone outpatients. Am.Drug Alcohol Abuse. 19:107

• Karp-Gelernter, E., Savage C., McCabe, O.L.(1982). Evaluation of clinic attendance schedules for LAAM and methadone a controlled study. International Journal of the Addictions. 17: 805-813.

• Kreek MJ.(1973) Plasma and urine levels of methadone. NY State J. Med.73: 2773-2777.

• Kreek MJ.(1976)Rifampicin- induced methadone withdrawal. New England Journal of Medicine. 294:1104-1106.

• Kreek MJ.(1979) Methadone in treatment physiological and pharmacological issues In: Handbook on drug abuse. Dupont R. Goldstein A. Eds.. Washington D.C. U.S. Govt. Printing Office.

• Kutin J, Lintzeris N.(1997). Introduction and background to the feasibility research. In: Expanding treatment options from heroin dependence in Victoria: buprenorphine, LAAM, naltrexone and slow release oral morphine. New pharmacotherapies projectfeasibility phase. Ritter A., Kutin J., Lintzeris n., Bammer G eds. Fitzroy, Victoria.Turning Point Alcohol

and drug centre Inc. Chapter 1:1-10.

• Ling W. (1978) Levo-alpha-acetylmethadol (LAAM) for opiate addiction. Current Psychiatric Therapies. 18: 173-180.

• Ling W (1994). Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs. 26:119-128.

• Ling W y Rawson R.A. (1997).American opiate substitution treatment programs:From methadone to LAAM and Buprenorphine. In:.The medical prescription of narcotics: Scientific foundation and practical experiencies. D.Lewis C. Gear,M.Laubli Loud, y D. Langenic-Cartwright eds. Gottingen: Hogrefe y Huber. 250-263.

• Loimer N, Schmid R. (1992).The use of plasma levels to optimize methadone maintenance treatment. Drug and Alcohol Dependence.30.:241-246.

• López ML, Baño MD, Agujetas M, Guillén JL (2000). Algoritmo del seguimiento de niveles plasmáticos de metadona en pacientes HIV en tratamiento con nevirapina. Adicciones.12(1):109.

• McEvoy GK.(1990) AHFS Drug Information 90. American Hospital Formulary Serviced. Bethesda: American Society of Hospital Pharmacists Inc.

• MacMahan, R.F., Culp, H.W., & Marshall, F.J.(1965) The metabolism of l-acetylmethadol in the rat: The identification of the probable active metabolite. Journal of Pharmacology and Experimental Therapeutics.

: 436-445.

• McLachlan C, Crofts N,Wodak A, Crowe S.(1993). The effects of mehtadone on immune function among injecting drug users: A review. Addiction .88:257-263.

• Micó Segura JA, Rojas Corrales MO, Moreno Brea.R.(1999) Interacciones medicamentosas de la metadona. Farmaceúticos.50-54.

• Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. (1997). The involvement of cytochrome P450 3A4 in the N-demethylation of L-alfa-acetylmethadol (LAAM). NLAAM and methadone. Drug Met Disp . 25

(12): 1347-1353.

• Nightingale,S.L.(1993). Levomethadyl approved for treatment of opiate dependence. J.Am Med Assoc 270:1290.

• Nilson MI, Meresaar U, Anggard E. (1982). Clinical pharmacokinetics of methadone. Acta Anesthesiol Scand .74, suppl: 66-69.

• Otero MJ. Fuertes A, Sanchez R., Luna G.( 1999). Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert. AIDS Vol. 13.1004-1005

• Quinn DI, Wodak A, O¨Day R, Colling JM, Strong JM. (1997).Pharmacokinetic and Pharmacodynamic principles of illicit drug and treatment of illict drug users. Clin Pharmacokinetic .33 (5): 344-400.

• Rawson, R.A., Ling, W. (1993).Levo-alpha-acetylmethadol (LAAM) for the Treatment of Opiate Dependence. A White Paper. Prepared for the California Office of Alcohol and Drug Programs.

• Rawson R.A., Hasson A.L., Huber A.M. Mccann M.J., Ling W. (1998) A 3- year progress report on the implementation of LAAM in the United States. Addiction . 93 (4):533-540.

• Roberts M, Franklin M.R.(1979).Modification of hepatic microsomal oxidative drug metabolism in rats by the opiate maintenance drug acetylmethadol, proposxyphene and methadone. Life Science Washington D.C. 25:845-852

• Reno RR,Aiken LS.(1993).Live activities and life quality of heroin addicts in and out of treatment. Int J.Addict. 28:211-232.

• Resnick RB, Washton AM, Garwood J, Perzel J.(1981) LAAM instead of take-home methadone. In L.S. Harris (Ed.). Problems of drug dependence. NIDA Research Monograph, Rockwille, MD. National Institute on Drug

Abuse. 41: 473-475.

• San L. (1997). El LAAM. Nueva alternativa en tratamientos de mantenimiento con sustitutivos". En: Tratamientos sustitutivos en dependencias a opiáceos. Metadona, LAAM, Heroína. Avances en farmacología de drogodependencias. Universidad de Deusto.37-56.

• Savage C, Karp EG, Curran S.F, Hanlon TE., McCabe O.L. (1976). Methadone/LAAM maintenance: a comparison study. Comprehensive Psychiatry. 17: 415-424.

• Sawe J. (1986). High-dose morphine and methadone in cancer patients: Clinical Pharmacokinetic considerations of oral treatmen. Clin Pharmacokinetic.11: 87-106.

• Seivewright NA,Greenwood J.(1996). What is important in drug misuse treatment?.Lancet 373-375

• Shuster CR. (1991) The National Institute on Drug Abuese and methadone maintenance treatment. J.Psychoact. Drugs. 23:111-112.

• Stimmel B (1993). Intravenous drug use, methadone and AIDS. Ask not for whom the bell tolls. J.Addict Dis. 12:1.

• Sullivan HR, Due Sl. (1973). Urinary metabolites of methadone, in maintenance subjects. J. Med. Chem. 16: 909-913.

• Sung C. & Way FL. (1954)The fate of optical isomers of aacetylmethadol. Journal of Pharmacology and Experimental Therapeutics . 110: 260-270.

• Tennant FS, Rawson RA, Pumphrey E, Seecof R. (1986). Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol. J Subst Abuse Treat. 3: 195-202.

• Tong TG, Pond S, Kreek MJ, Jaffery N, Benowitz N(1981).Phenytoin induced methadone withdrawal. Ann. Intern. Med. 94: 349-351.

• Torrens M, Castillo C, San L, Moral E, González ML, De la Torre R (1998). Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug and Alcohol dependence . 52:193-200.

• Walsh S.L, Johnson R.E, Cone E.J Bigelow G.E(1998). Intravenous and oral l-alfa-acetymethadol: Pharmacodynamics and Pharmacokinetic in humans. J. Pharmacol. Exp.Ther. 285: 71-82.

• Ward J, Mattick R, Hall W. ( 1992) Key issues in methadone maintenance treatment. Australia, University of Nes South Wales Press.

• Wolff K, Sanderson M, Hay A, Raistrick D. (1991). Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem . 37: 205-209.

• Wolff K. Hay A. Raistrick D. Calvert R.(1993). Steady –state pharmacokinetics of methadone in opioid addicts. Eur. J. Clin. Pharm. 44:189-194.

• Wolff K, Rostami , Hodjegan A, Shires S, Hay A, Feely M, Calvert R, Raistrick D. (1997). The pharmacokinetics of Methadone in healthy subjects and opiate users. Clin Pharmacol. 44: 325-334.

• Wolff K, Strang J. (1999) Therapeutic drug monitoring for methadone: Scanning the horizon. Eur. Addict Res. 5:36-42.

• Zannini A, Nizzoli U,Bussolati N.(1997).Valoración y seguimiento de los tratamientos con metadona:índice de retención,marcadores biológicos y comportamentales. Adicciones.9 (3):457-466.




DOI: https://doi.org/10.20882/adicciones.566

Enlaces refback

  • No hay ningún enlace refback.